Volume 31, Issue 1 pp. 7-11
Original Article
Free Access

Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study

Naga Chalasani M.D.

Corresponding Author

Naga Chalasani M.D.

Indiana University School of Medicine, Indianapolis, IN

Indiana University School of Medicine, WD OPW 2005, 1001 W. 10th Street, Indianapolis; IN 46202===Search for more papers by this author
Arthur Baluyut

Arthur Baluyut

Indiana University School of Medicine, Indianapolis, IN

Search for more papers by this author
Ayaaz Ismail

Ayaaz Ismail

Emory University School of Medicine, Atlanta, GA

Search for more papers by this author
Atif Zaman

Atif Zaman

Oregon Health Sciences University, Portland, OR

Search for more papers by this author
Gagan Sood

Gagan Sood

Gagan Sood and the UAB Liver Center, University of Alabama at Birmingham, Birmingham, AL

Search for more papers by this author
Reem Ghalib

Reem Ghalib

University of Texas at Houston, Houston, TX

Search for more papers by this author
T. M. McCashland

T. M. McCashland

University of Nebraska Medical Center, Omaha, NE

Search for more papers by this author
K. Rajender Reddy

K. Rajender Reddy

University of Miami Medical Center, Miami, FL

Search for more papers by this author
Xaralambos Zervos

Xaralambos Zervos

University of Miami Medical Center, Miami, FL

Search for more papers by this author
Mann A. Anbari

Mann A. Anbari

Saint Louis University, St Louis, MO

Search for more papers by this author
Helena Hoen

Helena Hoen

Indiana University School of Medicine, Indianapolis, IN

Search for more papers by this author
First published: 30 December 2003
Citations: 275

Abstract

Patients with primary sclerosing cholangitis (PSC) have a significantly increased risk of developing cholangiocarcinoma (CCA). Risk factors for developing such a complication are not well defined. We conducted a multicenter, case-control study to determine the risk factors and possible predictors for CCA in patients with PSC. The demographic, clinical, and laboratory features of 26 PSC patients with CCA diagnosed over a 7-year period at eight academic centers were compared with 87 patients with PSC but no CCA (controls). There was no statistically significant difference in demographics, smoking, signs or symptoms or complications of PSC, indices of disease severity (Mayo Risk score or Child-Pugh score), frequency or duration or complications of inflammatory bowel disease (IBD), frequency of biliary surgery, or therapeutic endoscopy between the two groups. Alcohol consumption was significantly associated with CCA in patients with PSC (odds ratio: 2.95; 95% CI: 1.04-8.3). Serum carbohydrate antigen 19-9 (CA 19-9) was significantly higher in patients with CCA than those without (177 ± 89 and 61 ± 58 U/mL, respectively;P = .002). A serum CA 19-9 level > 100 U/mL had 75% sensitivity and 80% specificity in identifying PSC patients with CCA. In conclusion, alcohol consumption was a risk factor for having CCA in PSC patients. The indices of severity of liver disease were not associated with CCA in patients with PSC. Serum CA 19-9 appeared to have good ability to discriminate PSC patients with and without CCA.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.